World Investment Advisors lifted its position in Novartis AG (NYSE:NVS – Free Report) by 12.9% in the 4th quarter, Holdings Channel reports. The fund owned 50,214 shares of the company’s stock after acquiring an additional 5,719 shares during the quarter. World Investment Advisors’ holdings in Novartis were worth $6,435,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Todd Asset Management LLC increased its position in Novartis by 5.8% during the 3rd quarter. Todd Asset Management LLC now owns 439,879 shares of the company’s stock valued at $56,411,000 after buying an additional 23,978 shares in the last quarter. Lockheed Martin Investment Management Co. increased its position in Novartis by 15.6% during the 3rd quarter. Lockheed Martin Investment Management Co. now owns 85,200 shares of the company’s stock valued at $10,926,000 after buying an additional 11,500 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Novartis by 5.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 132,536 shares of the company’s stock valued at $17,001,000 after buying an additional 6,924 shares in the last quarter. Fisher Asset Management LLC increased its position in Novartis by 1.7% during the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock valued at $928,376,000 after buying an additional 117,952 shares in the last quarter. Finally, BXM Wealth LLC boosted its stake in Novartis by 726.9% during the 4th quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock valued at $5,903,000 after purchasing an additional 37,639 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. TD Cowen reissued a “hold” rating on shares of Novartis in a report on Tuesday, February 17th. Argus raised Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Wednesday, March 11th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Sanford C. Bernstein raised Novartis to a “hold” rating in a report on Thursday, March 19th. Finally, Morgan Stanley lifted their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $141.20.
Novartis Stock Performance
Shares of NVS opened at $149.73 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis AG has a one year low of $104.93 and a one year high of $170.46. The firm has a market capitalization of $285.70 billion, a P/E ratio of 21.45, a PEG ratio of 2.60 and a beta of 0.46. The business has a fifty day moving average of $151.61 and a 200 day moving average of $144.75.
Novartis (NYSE:NVS – Get Free Report) last issued its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. During the same period in the previous year, the firm earned $2.28 EPS. The business’s revenue was down .9% on a year-over-year basis. As a group, sell-side analysts anticipate that Novartis AG will post 8.85 EPS for the current year.
About Novartis
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
Featured Articles
- Five stocks we like better than Novartis
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
